PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Positive EBIT growth while AVXL is negative. John Neff might see a substantial edge in operational management.
-121.69%
Negative operating income growth while AVXL is at 5.19%. Joel Greenblatt would press for urgent turnaround measures.
-139.60%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-131.82%
Negative EPS growth while AVXL is at 0.00%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-131.82%
Negative diluted EPS growth while AVXL is at 0.00%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-31.70%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-31.70%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative 3Y CAGR while AVXL stands at 0.00%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
95.37%
Positive long-term OCF/share growth while AVXL is negative. John Neff would see a structural advantage in sustained cash generation.
75.95%
Positive OCF/share growth while AVXL is negative. John Neff might see a comparative advantage in operational cash viability.
7.00%
Positive 3Y OCF/share CAGR while AVXL is negative. John Neff might see a big short-term edge in operational efficiency.
81.58%
Positive 10Y CAGR while AVXL is negative. John Neff might see a substantial advantage in bottom-line trajectory.
47.75%
Positive 5Y CAGR while AVXL is negative. John Neff might view this as a strong mid-term relative advantage.
-122.09%
Negative 3Y CAGR while AVXL is 0.27%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
-94.45%
Negative equity/share CAGR over 10 years while AVXL stands at 3468.06%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
58.16%
Below 50% of AVXL's 175.95%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
-73.50%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-10.73%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-21.56%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-8.90%
We’re deleveraging while AVXL stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
60.05%
We increase R&D while AVXL cuts. John Neff sees a short-term profit drag but a potential lead in future innovations.
231.77%
SG&A growth well above AVXL's 13.12%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.